e-learning
resources
ERJ
2003
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment
Harsch I.A., Konturek P.C., Koebnick C., Kuehnlein P.P., Fuchs F.S., Pour Schahin S., Wiest G.H., Hahn E.G., Lohmann T., Ficker J.H.
Source:
Eur Respir J 2003; 22: 251-257
Journal Issue:
August
Disease area:
Sleep and breathing disorders
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Harsch I.A., Konturek P.C., Koebnick C., Kuehnlein P.P., Fuchs F.S., Pour Schahin S., Wiest G.H., Hahn E.G., Lohmann T., Ficker J.H.. Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. Eur Respir J 2003; 22: 251-257
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Clinical case discussion: ERS guidelines on high flow nasal cannula in acute respiratory failure: from the clinical cases to the scientific evidence
Adherence predictors to positive airway pressure (PAP) treatment in patients with obstructive sleep apnea (OSA)
The search for realistic evidence on the outcomes of obstructive sleep apnoea
Related content which might interest you:
Metabolic disturbances in patients with obstructive sleep apnoea syndrome
Source: Eur Respir Rev 2007; 16: 196-202
Year: 2007
Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome
Source: Eur Respir J 2004; 24: Suppl. 48, 332s
Year: 2004
Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP
Source: Eur Respir J 2007; 30: 496-500
Year: 2007
Effect of continuous positive airway pressure treatment on hypoadiponectinemia in male patients with obstructive sleep apnea syndrome
Source: Annual Congress 2005 - Metabolic control in OSA
Year: 2005
Effect of 8 week CPAP therapy on insulin resistance, serum leptin and lipid concentrations among obstructive sleep apnea hypopnea syndrome (OSAS) patients
Source: Eur Respir J 2004; 24: Suppl. 48, 330s
Year: 2004
Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients
Source: Eur Respir J 2009; 34: 694
Year: 2009
Impact of obstructive sleep apnoea (OSA) on glucose metabolism
Source: Annual Congress 2007 - Cardiovascular and metabolic consequences of obstructive sleep apnoea: early changes, biomarkers and impact of treatment
Year: 2007
The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome
Source: Eur Respir J 2004; 24: Suppl. 48, 113s
Year: 2004
The effect of theophylline and CPAP on cytokine release in patients with obstructive sleep apnea syndrome (OSAS)
Source: Eur Respir J 2006; 28: Suppl. 50, 216s
Year: 2006
Angio-inhibitory activity and decreased leptin level in sera from obstructive sleep apnea syndrome (OSAS) patients
Source: Eur Respir J 2001; 18: Suppl. 33, 334s
Year: 2001
The influence of 3-weeks‘ therapy of continous positive airway pressure (CPAP) on serum leptin and homocysteine concentration in patients with obstructive sleep apnea (OSA)
Source: Annual Congress 2005 - Metabolic control in OSA
Year: 2005
Plasma adiponectin levels and hypoxic stress in patients with obstructive sleep apnea syndrome (OSAS)
Source: Annual Congress 2004 - Systemic and metabolic effects from OSA
Year: 2004
Elevated leptin is associated with impaired glucose tolerance in obstructive sleep apnoea (OSA)
Source: Eur Respir J 2006; 28: Suppl. 50, 573s
Year: 2006
Influence of treatment on leptin levels in patients with obstructive sleep apnoea
Source: Eur Respir J 2004; 23: 601-604
Year: 2004
Should obstructive sleep apnoea be treated regarding the related cardiovascular risk in non sleepy patients?
Source: Annual Congress 2006 - Obstructive sleep apnoea and cardiovascular diseases
Year: 2006
Serum leptin levels in obstructive sleep apnoea patients
Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea
Year: 2007
CPAP decreases plasma levels of soluble tumour necrosis factor-α receptor 1 in obstructive sleep apnoea
Source: Eur Respir J 2008; 32: 1009-1015
Year: 2008
Effect of continuous positive airway pressure therapy on metabolic control in patients with morbid obesity and obstructive sleep apnoea
Source: Annual Congress 2013 –Burn after reading: inflammation in sleep disordered breathing
Year: 2013
Cardiovascular and metabolic effects of CPAP in obese males with OSA
Source: Eur Respir J 2007; 29: 720-727
Year: 2007
Effects of CPAP treatment on physical fitness in patients with obstructive sleep apnoea syndrome (OSAS)
Source: Eur Respir J 2003; 22: Suppl. 45, 97s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept